Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2025)

Harmony Biosciences Holdings' Non-Current Debt history spans 7 years, with the latest figure at $143.7 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 11.87% year-over-year to $143.7 million; the TTM value through Dec 2025 reached $143.7 million, down 11.87%, while the annual FY2025 figure was $143.7 million, 11.87% down from the prior year.
  • Non-Current Debt for Q4 2025 was $143.7 million at Harmony Biosciences Holdings, down from $148.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $195.6 million in Q2 2021 and bottomed at $143.7 million in Q4 2025.
  • The 5-year median for Non-Current Debt is $181.3 million (2023), against an average of $176.8 million.
  • The largest annual shift saw Non-Current Debt decreased 0.18% in 2022 before it fell 11.87% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $190.0 million in 2021, then decreased by 0.18% to $189.6 million in 2022, then fell by 5.84% to $178.6 million in 2023, then dropped by 8.71% to $163.0 million in 2024, then fell by 11.87% to $143.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Non-Current Debt are $143.7 million (Q4 2025), $148.5 million (Q3 2025), and $153.3 million (Q2 2025).